Patent application number | Description | Published |
20080242725 | Pharmaceutical Composition - Stabilized pharmaceutical compositions comprising polymorphs of active pharmaceutical ingredients susceptible to conversion to alternate polymorph forms are prepared by a process of wet granulation in which the ratios of active, fillers, and granulating liquid are controlled in order to avoid polymorphic interconversions. | 10-02-2008 |
20090012150 | Stablized Pharmaceutical Composition Comprising an Amorphous Active Substance - The invention relates to the pharmaceutical composition comprising the amorphous active substance which is atorvastatin calcium. The process of stabilization of the pharmaceutical composition comprising the pharmaceutical formulation with amorphous atorvastatin calcium, the process of stabilization of the pharmaceutical formulation comprising amorphous atorvastatin calcium and the process of stabilization of atorvastatin calcium in an amorphous form is described. | 01-08-2009 |
20100056605 | OXIDATIVE DEGRADATION PRODUCTS OF ATORVASTATIN CALCIUM - The present invention relates to oxidative degradation products of atorvastatin calcium and the process of the preparation thereof. The present invention also relates to atorvastatin calcium substantially free of oxidative degradation products and the pharmaceutical compositions containing such atorvastatin calcium. | 03-04-2010 |
20100190958 | PURE VANCOMYCIN HYDROCHLORIDE - The new pure vancomycin hydrochloride substantially free of impurities known in commercially available products is described. The term “substantially free of impurities” designates a purity of vancomycin hydrochloride between about 97% and about 99%, particularly between about 98% and about 99%, preferably about 99%, as determined by HPLC analytical method as directed in U.S.P., NF 27th revision, 22 (2004). The new pure vancomycin hydrochloride (vancomycin B hydrochloride) contains less than 0.7% of total impurities, namely, only one impurity exceeds 0.3%. The new process for the purification of crude vancomycin by displacement chromatography is described by which the desired pure antibiotic according to the present invention is produced, based on the finding that high purity of the vancomycin hydrochloride is obtained using low selected pH values of the mobile phase between 3.9 and 4.2. Vancomycin hydrochloride is the known antibiotic which is used for the treatment of severe staphylococcal infections, especially those caused by methicillin-resistant staphylococcal strains. | 07-29-2010 |
20100219063 | OXIDATIVE DEGENERATION PRODUCTS OF ATORVASTATIN CALCIUM - The present invention relates to oxidative degradation products of atorvastatin calcium and the process of the preparation thereof. The present invention also relates to atorvastatin calcium substantially free of oxidative degradation products and the pharmaceutical compositions containing such atorvastatin calcium. | 09-02-2010 |
20110112165 | ATORVASTATIN-ALISKIREN - A new compound in which atorvastatin and aliskiren are covalently bound, salts of this compound, pharmaceutical compositions thereof, as well the use of this compound as a medicament and as an impurity standard are provided. Furthermore, a 0 process for the preparation of a compound in which atorvastatin and aliskiren are covalently bound, a method for analyzing a sample of atorvastatin and/or aliskiren, and a method for determining the retention time on a chromatographic system for atorvastatin and/or aliskiren are provided. | 05-12-2011 |
20110184172 | PROCESS FOR THE PREPARATION OF METHYL ESTER OF ROSUVASTATIN - Process for the preparation of enantiomerically pure methyl ester of rosuvastatin has been developed, wherein the crude methyl ester ester is first purified by preparative chromatography, followed by crystallization. | 07-28-2011 |
20150105551 | OXIDATIVE DEGRADATION PRODUCTS OF ATROVASTATIN CALCIUM - The present invention relates to oxidative degradation products of atorvastatin calcium and the process of the preparation thereof. The present invention also relates to atorvastatin calcium substantially free of oxidative degradation products and the pharmaceutical compositions containing such atorvastatin calcium. | 04-16-2015 |